Recognizing February 19, 2026, As World Cholangiocarcinoma Day In The State Of Delaware.
Summary
SCR 146 is a ceremonial Senate Concurrent Resolution that recognizes February 19, 2026, as “World Cholangiocarcinoma Day” in Delaware. The resolution highlights cholangiocarcinoma, also known as bile duct cancer, as a rare and often late-diagnosed cancer with a low five-year survival rate, and it cites the work of the Cholangiocarcinoma Foundation, Team Cure Cholangio, and other advocacy and research organizations in raising awareness and funding research.
The resolution does not create a regulatory program, mandate state spending, or amend Delaware law. Instead, it expresses the General Assembly’s support for public awareness, research, and continued efforts toward better treatment and a cure. It also places Delaware on record as joining broader observances intended to educate the public and encourage early detection and research into this disease.
Impact
SCR 146 has no direct legal or fiscal effect on state statutes, agencies, or regulated parties. Its impact is symbolic and commemorative: it designates a day of recognition in Delaware and signals legislative support for cancer awareness, research funding, and advocacy related to cholangiocarcinoma. Any practical effect would be indirect, through public education and encouragement of charitable, medical, and research efforts.
Sentiment
The overall sentiment around the resolution is strongly supportive and noncontroversial. The bill passed the Senate third reading unanimously, 20-0, indicating broad bipartisan agreement. The text and context frame the measure as a compassionate recognition of a serious disease and a show of support for patients, families, researchers, and advocacy groups.
Contention
No notable opposition or substantive contention appears in the bill text or voting history. Because the resolution is honorary and awareness-focused, there is no indication of disagreement over policy, funding, or implementation. The only implicit point of emphasis is the need for greater research and earlier detection for a disease described as rare, underfunded, and often diagnosed late.